Примери за използване на Treatment with imatinib на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Resume treatment with imatinib at 600 mg.
Do not breast-feed during the treatment with Imatinib Accord.
Treatment with imatinib may then be continued at a reduced daily dose.
Patients should be tested for HBV infection before initiating treatment with Imatinib Accord.
After that, treatment with imatinib may be continued at a reduced daily dose.
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed.
Ph+ CP CML with prior treatment with imatinib and dasatinib or nilotinib.
It is also used in patients who have a T315I mutation which makes them resistant to treatment with imatinib, dasatinib or nilotinib.
In clinical trials, treatment with imatinib was continued until disease progression.
However, patients should be advised that they may experience undesirable effectssuch as dizziness or blurred vision during treatment with imatinib.
The long-term effects of prolonged treatment with imatinib on growth in children are unknown.
Treatment with imatinib may be interrupted or the dose may be reduced, as recommended in section 4.2.
In clinical trials in GIST patients, treatment with imatinib was continued until disease progression.
Unresectable or metastatic gastrointestinal stromal tumours(GIST) who progressed on orare intolerant to prior treatment with imatinib and sunitinib.
During treatment with Imatinib Teva, tell your doctor straight away if you put on weight very quickly.
Muscle cramps or joint, muscle or bone pain, during treatment with Imatinib Teva or after you have stopped taking Imatinib Teva.
During treatment with Imatinib Accord, tell your doctor straight away if you put on weight very quickly.
It is also used in patients who have a genetic mutation called‘T315I mutation' which makes them resistant to treatment with imatinib, dasatinib or nilotinib.
Long-term treatment with imatinib may be associated with a clinically significant decline in renal function.
Treatment with imatinib for 36 months was superior to treatment for 12 months in the ITT analysis, i.e. including the entire study population.
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib(see section 4.5).
Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing.
An open-label, single-arm, multicentre study was conducted in patients resistant orintolerant to imatinib(i.e. patients who experienced significant toxicity during treatment with imatinib that precluded further treatment). .
Patients with GIST should have tried treatment with imatinib and sunitinib and patients with HCC should have tried sorafenib before starting treatment with Stivarga.
A Phase 3, randomised, double-blind, placebo-controlled study of sunitinib was conducted in patients with GIST who were intolerant to, or had experienced disease progression during or following treatment with imatinib(median maximum daily dose 800 mg).
Do not breast-feed during the treatment with Imatinib Teva B.V.- Patients who are concerned about their fertility while taking Imatinib Teva B.V. are advised to consult.